Atai Life Sciences N.V. (ATAI) Quarterly EPS earnings growth

atai Life Sciences Corp - graphic logo of issuer ATAI

Atai Life Sciences N.V. (ATAI) is currently utilizing its accumulated reserves to conduct clinical trials. Investments in unique molecules are establishing a foundation for future revenues. The quarterly earnings per share trend captures the real momentum, where the 36.00 level reflects the current magnitude. However, the path to success is complicated by stringent FDA and DEA oversight, as well as colossal R&D expenditures.

atai Life Sciences (ATAI) - Year-over-year earnings per one share growth for the last 12 months from 07/04/2022 to 09/26/2026

ATAI (atai Life Sciences): analytical breakdowns and indicator data

- share price and consensus valuation forecast:
Fundamental company valuation:atai Life Sciences NV - ATAI
Flagship merchandise of atai.life

Quarterly EPS growth measures the percentage change in net income per share compared to the same period last year. This metric reflects profit generation efficiency and reacts sensitively to any adjustments in financial reporting. By analyzing the quarterly earnings per share growth chart on GURU.Markets, an investor can identify the gap between the market price and actual earnings. For Atai Life Sciences N.V. (ATAI), this indicator is critical, as the business depends on regulatory approvals for psychedelic therapies. Access to capital determines the platform's ability to maintain positive momentum for this metric.

Competitor analysis

ALKS (alkermes.com) - Year-over-year net earnings per share growth for the last 12 months|Earnings per share growth in annualized terms for the last twelve months Avadel Pharma (AVDL)|GHRS (ghres.com) - Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months Mind Medicine (MNMD)|Quarterly EPS earnings growth CMPS|LBRX (LB Pharmaceuticals, Inc.) - Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months brightmindsbio.com DRUG|Vanda Pharmaceuticals (VNDA) - Earnings per share growth in annualized terms for the last twelve months|Cybin - Quarterly EPS earnings growth|ANRO - Quarterly EPS earnings growth|NRx Pharmaceuticals, Inc. (NRXP) - Year-over-year earnings per share growth for the last twelve months|CING - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Silo Pharma, Inc.|chinapharmaholdings.com (CPHI) - Year-over-year net earnings per share change for the last twelve months|Quarterly EPS earnings growth CMND|Psyence Biomedical Ltd. - Year-over-year earnings per share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months SciSparc Ltd SPRC|Seelos Therapeutics Inc. (SEEL) - Earnings per share growth in annualized terms for the last twelve months|VRPX: Year-over-year net earnings per share growth for the last 12 months|KRTX - Quarterly EPS earnings growth